Parameter
| Biomarker | ABRS-P | Full name | AFP-Based Risk Score - Pathological | Molecular Type | Composite index (morphology +RNA signature) |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Diagnosis, prognosis, and prediction of treatment response | ||
| Disease | Hepatocellular Carcinoma (HCC) | Disease Subtypes | / | ||
| Organ | Liver | Test Sample / Technology Platform | Serum/plasma (ELISA, RIA) | ||
| Pathobiological Mechanisms | Liver cancer cell abnormal expression of embryonic proteins, involved in tumor proliferation and immune suppression | ||||
| Clinical Availability Status | Clinical available (routine screening) : separate the detection sensitivity, 47-64% combined ultrasonic can be improved to 63% | ||||
| Notes and Dynamics | The traditional core marker, AFP≥400 ng/mL, can predict the benefit of ramucirumab treatment. A decrease of >20% at 2-8 weeks after treatment indicated a good response | ||||